DUBLIN--(BUSINESS WIRE)--ERS Genomics Limited (‘ERS’) is pleased to announce ATLATL Innovation Centre (‘ATLATL’) as its non-exclusive agent for licensing ERS’ intellectual property for commercial ...

Cas9 is directed to its target within the DNA sequence through the use of the guide RNA. A specific sequence of DNA that is between two and five nucleotides in length must align with the 3’ end of the ...

Crispr Therapeutics, a leader in CRISPR/Cas9 biotechnology, recently received FDA and EMA approval for Casgevy, the first CRISPR/Cas9-based treatment for TDT and SCD. The partnership with Vertex ...

Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a progressive, often fatal disease. Nexiguran ziclumeran (nex-z) is an investigational therapy based on CRISPR-Cas9 (clustered regularly ...

The Food and Drug Administration on Friday approved two gene therapies to treat sickle cell disease, one of the which is the first CRISPR/Cas9-based treatment to win regulatory approval in the US. The ...

A new study published in Nature Communications demonstrates how small molecule inhibitors can be used to improve the precision and efficiency of CRISPR-Cas9 gene editing. The results demonstrate how ...

Scientists introduced CRISPR to the world as a gene-editing tool in summer 2012, when landmark papers from two independent groups demonstrated how the system could be wielded to make cuts in DNA. Now, ...

Researchers have now used a gene-drive system to suppress an important agricultural pest. Researchers have developed a "homing gene drive system" based on CRISPR/Cas9 that could be used to suppress ...

CHICAGO – A CRISPR-Cas9-based investigational therapy was linked with a drop in serum transthyretin (TTR) levels in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), according to ...